CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
Tipifarnibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02464228
NCT02464228Phase 2Completed
CompareCT.gov

An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

Kura Oncology, Inc.·interventional·Posted Jun 8, 2015·Updated Jun 26, 2024

In Brief

A Phase 2 clinical trial evaluating Tipifarnib for Relapsed or Refractory Peripheral T-Cell Lymphoma. Completed, enrolled 65 participants across 13 sites in 3 countries.

Detailed Summary

Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL). Tipifarnib will be administered orally until disease progression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed or Refractory Peripheral T-Cell Lymphoma
CountriesSouth Korea, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 8, 2015
Enrollment StartFeb 25, 2016
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 11.1 years ago

Interventions

Tipifarnibdrug

oral